REAL-WORLD EFFECTIVENESS OF SEMAGLUTIDE AND SGLT-2I VS SGLT-2I ALONE ON KIDNEY AND CARDIOVASCULAR OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/7f6174e2f3956339927578e7f8f324de.pdf
REAL-WORLD EFFECTIVENESS OF SEMAGLUTIDE AND SGLT-2I VS SGLT-2I ALONE ON KIDNEY AND CARDIOVASCULAR OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Katherine
Tuttle
Edouard Fu e.l.fu@lumc.nl Leiden University Medical Center Department of Clinical Epidemiology Leiden Netherlands -
Peter Bruun-Rasmussen PBRZ@novonordisk.com Novo Nordisk A/S Data Scientist Søborg Denmark -
David Cherney David.Cherney@uhn.ca University of Toronto Department of Medicine Toronto Canada -
Christine Fuchs Jacobsen CIJB@novonordisk.com Novo Nordisk A/S Medical & Science Søborg Denmark -
Carolien C. H. M. Maas c.h.m.maas@lumc.nl Leiden University Medical Center Department of Clinical Epidemiology Leiden Netherlands -
Manuel Maximilian Mayrdorfer MUMF@novonordisk.com Novo Nordisk A/S GMA Søborg Denmark -
Alex Mourer OAXM@novonordisk.com Novo Nordisk A/S Senior Data Scientist Søborg Denmark -
Brendon Neuen bneuen@georgeinstitute.org.au Royal North Shore Hospital George Institute for Global Health Sydney Australia -
Nils Skajaa NXCS@novonordisk.com Novo Nordisk A/S Real-World Evidence Søborg Denmark -
Katherine Tuttle Katherine.Tuttle@providence.org University of Washington Nephrology Division and Kidney Research Institute Seattle United States *
-
-
-
-
-